Climen is commonly used for Menopausal Hormone Therapy (MHT) and is relevant in contexts involving heightened systemic burden related to Estrogen Deficiency. This medication is relevant across domains where additional symptomatic support is needed. The core therapeutic indications are centered on hormone replacement and addressing clinical symptoms of menopause.

This therapy primarily supports the management of vasomotor symptoms (such as hot flashes and night sweats) and symptoms of urogenital atrophy (like vaginal dryness and irritation). It is also applicable as an adjunct therapy for the prevention of postmenopausal osteoporosis in high-risk women. The combination formulation is commonly used when supportive symptom management is appropriate, particularly where Endometrial protection is needed for patients with an intact uterus. It is used in situations involving certain distressing symptoms, contributing to easing the overall symptom load and helping improve day-to-day comfort.

Quick Fact: Relief for Vasomotor Symptoms (Hot Flashes, Night Sweats) and Urogenital Atrophy (Vaginal Dryness).

Regulatory References

1. European Medicines Agency

Eligibility: Who Can and Cannot Use Climen?

Eligibility for Climen (estradiol valerate/cyproterone acetate) is strictly defined by regulatory documents, primarily restricting use to postmenopausal women who do not have specific high-risk medical conditions.

Climen is contraindicated (must not be used) in patients with the following conditions or statuses:

• Vascular/Thromboembolic History: Current or previous venous or arterial blood clots (e.g., DVT, PE, stroke, heart attack) or known thrombophilic disorders.
• Malignancy: Current or previous breast cancer, or any suspected oestrogen-dependent malignant tumours (e.g., endometrial carcinoma).
• Hepatic Status: Severe liver disease, liver tumours, or abnormal liver function test results that have not returned to normal.
• Other Conditions: Undiagnosed vaginal bleeding, untreated endometrial hyperplasia, a history of meningioma, or porphyria.

Population Status	Eligibility Rule
Pregnancy/Lactation	Contraindicated (prohibited use).
Paediatric Population	Not indicated (formally excluded).

Use is conditional upon the absence of all contraindicated conditions. Patients with pre-existing conditions like diabetes, hypertension, or mild hepatic impairment require strict medical monitoring.

Interactions with Other Medicines and Products

The official interaction profile for Climen (Estradiol valerate and Cyproterone acetate) is defined by pharmacokinetic changes in hormone exposure and a pharmacodynamic effect on glucose metabolism. This information is documented in regulatory sources and outlines specific restrictions and constraints.

Pharmacokinetic and Pharmacodynamic Interactions

Category	Documented Interaction Pattern
Enzyme Induction	Co-administration with enzyme-inducing substances, such as Rifampicin, Barbiturates, Hydantoins, or Phenylbutazone, accelerates the metabolism of the steroid hormones and may impair the intended therapeutic effect.
Intestinal Flora Alteration	Certain antibiotics (e.g., Ampicillin) are documented to reduce the circulating steroid substance levels due to alteration of the intestinal flora.
Enzyme Inhibition	Strong inhibitors of the CYP3A4 enzyme (e.g., Ketoconazole) are expected to inhibit the metabolism of the Cyproterone acetate component, leading to increased plasma concentration and exposure.
Pharmacodynamic Effect	Climen may alter glucose tolerance. This requires medical supervision for patients with diabetes mellitus due to potential changes in the need for antidiabetic medicines.
Herbal Interactions	Herbal products that induce metabolic enzymes, such as St. John's Wort, may decrease the effectiveness of the estrogen component.

Regulatory Context and Constraints

The low-dose Cyproterone acetate component is documented in prescribing information as contraindicated as a precaution in patients with a current meningioma or a history of meningioma. Furthermore, the product is formally contraindicated in women with severe hepatic disease.

Climen's action is derived from its two active components: the estrogen estradiol valerate (E2V) and the progestin cyproterone acetate (CPA). E2V, a synthetic prodrug, is hydrolyzed to release 17beta-estradiol (E2). E2 functions by binding to the intracellular Estrogen Receptors (ER), specifically ER alpha and ER beta. This ligand-receptor complex enters the cell nucleus and interacts with specific DNA sequences known as Estrogen Response Elements (EREs).

This binding modulates gene transcription, thereby regulating the synthesis of numerous proteins in target tissues, including the hypothalamus, pituitary gland, and bone. CPA exerts its effects primarily through two distinct mechanisms. First, it binds to and activates the Progesterone Receptor (PR), thereby modifying cellular activity, particularly in the endometrium. Second, CPA acts as a competitive antagonist at the Androgen Receptor (AR), preventing the interaction of endogenous androgens with their receptors. This dual activity results in systemic modulation of the hypothalamic-pituitary axis and direct alteration of cellular signaling in reproductive tissues.

Climen is an oral sequential combined hormone replacement therapy (HRT) taken daily according to a specified 28-day cycle. This product consists of coated tablets with two distinct hormonal compositions and a tablet-free or non-hormonal tablet interval.

Administration and Dosing Schedule

Feature	Official Instruction
Route of Administration	Oral. Tablets must be swallowed whole with some liquid.
Dosing Cycle	One tablet taken daily for 28 consecutive days.
Regimen Sequence	Phase 1: 11 white tablets (Estradiol Valerate 2 mg) are taken first, followed by Phase 2: 10 pink tablets (Estradiol Valerate 2 mg plus Cyproterone Acetate 1 mg). The cycle concludes with a 7-day tablet-free interval or non-hormonal tablets.
Timing	Tablets must be taken at approximately the same time each day.

Procedural and Population-Specific Rules

Tablet-taking is initiated at the blister section marked "Start" and continues daily following the directional arrows until the pack is empty. Calendar packs often include day-of-the-week stickers to help track daily intake.

Starting Rules:

• Postmenopausal women (with amenorrhea): May begin the 28-day course on any day of their choosing, provided pregnancy is ruled out.
• Menstruating women: The first tablet must be taken on Day 5 of the menstrual cycle (Day 1 being the first day of bleeding).

Missed Dose:

If a tablet is missed at the usual time, it should be taken within 12 hours to help avoid the potential for breakthrough bleeding. If the period exceeds 12 hours, the missed tablet should be discarded, and the next tablet should be taken at the scheduled time. A new pack is started immediately after the last tablet or tablet-free interval of the previous pack, ensuring no interruption in the daily schedule.

Research Evidence / Overview of Studies for Climen

Evidence for use in Managing Vasomotor Symptoms

Research into this hormonal combination has been conducted using Randomized Controlled Trials (RCTs), a high standard for clinical evaluation. These studies were used in research exploring how symptoms change over time in postmenopausal women with an intact uterus who report complaints like hot flashes and night sweats. The trials primarily focused on measuring changes in the frequency and perceived intensity of these episodic or acute changes.

Findings from the HRT class, to which Climen belongs, generally describe patterns observed in measured changes to subjective symptom scores. Reported outcomes were short to intermediate-term, during which time researchers monitored the outcomes related to physical discomfort. The evidence remains limited, however, regarding the long-term patterns of symptom measurement beyond the first year for this specific product combination.

---

Evidence for Managing Urogenital Atrophy

Studies exploring this indication evaluated urogenital concerns, such as vaginal dryness and irritation, alongside primary measures in trials primarily focused on overall menopausal symptoms. These trials monitored changes in both patient-reported outcomes describing perceived discomfort and objective clinical measures like the Vaginal Maturation Index (VMI).

Because this symptom is frequently evaluated as a secondary measure, data for certain groups remain insufficient when looking for dedicated, large-scale RCTs focused exclusively on urogenital atrophy outcomes. The available research generally provides insight into short-term changes but does not offer extensive long-term data for this specific outcome.

---

Evidence for Preventing Postmenopausal Osteoporosis

Research has examined how this hormonal combination relates to bone health parameters. Intermediate-term clinical trials have been conducted to measure changes in Bone Mineral Density (BMD) at the hip and spine in postmenopausal women identified as being at high risk of fracture. The long-term data regarding the incidence of fracture events are primarily drawn from large-scale observational settings across the entire HRT class.

---

Key Studies & References

1. Prevention of femoral and lumbar bone loss with hormone replacement therapy and vitamin D3 in early postmenopausal women: a population-based 5-year randomized trial
2. Menopause: identification and management - NICE Guideline [NG23]
3. Climen Tablets - Summary of Product Characteristics (SPC) / Patient Information Leaflet (PIL) (Bayer)

Common questions about Climen (FAQ)

Q: How do I know when the tablet-free interval starts and ends?

The tablet-free interval begins following the completion of the 21 active tablets (the white and pink ones). This interval lasts for seven days. Regulatory directions state that the next pack is started exactly four weeks after the first tablet of the previous pack, which is how continuity is maintained on the same day of the week.

Q: Is Climen safe to use with alcohol?

Regulatory documents for Climen do not specifically caution against moderate alcohol use. However, official product information advises that the development of jaundice (yellowing of the skin or eyes) requires immediate discontinuation of the medicine. Since excessive alcohol consumption can contribute to liver impairment, and jaundice is a contraindication, information regarding individual alcohol consumption should be discussed with a healthcare provider.

Q: What specific measures are used to diagnose urogenital atrophy in the studies?

Studies examining the use of hormone therapy often rely on two key types of information to measure changes in urogenital atrophy. Researchers track patient-reported outcomes (PROs), which are subjective reports describing symptoms like irritation or dryness. They also use objective measures, such as the Vaginal Maturation Index (VMI), which is a clinical test to assess changes in the epithelial cells of the vaginal lining.

Q: Can men use Climen for any condition?

The official labeling indicates that Climen is not intended for use in men. The product is defined as a medicine indicated solely for Hormone Replacement Therapy (HRT). Its use is limited to the treatment of oestrogen deficiency symptoms and prevention of osteoporosis in the indicated female population (peri- and postmenopausal women).

️ How to Store and Dispose of Climen?

To ensure Climen (estradiol valerate and cyproterone acetate) maintains its effectiveness and safety, proper storage is essential.

Storage Guidelines

Condition	Requirement
Temperature	Store at room temperature (typically 20 C to 25 C or 68 F to 77 F).
Environment	Keep the blister pack in the original outer carton to protect the tablets from light and moisture.
Safety	Keep Climen and all medicines out of the sight and reach of children and pets.

---

Disposal

Do not dispose of Climen by flushing it down a toilet or throwing it into household waste. Unused or expired medication should be disposed of in accordance with local guidelines or a take-back program. Consult your pharmacist or local waste disposal company for information on safe and environmentally responsible disposal methods.